All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Myelodysplastic syndrome

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013753" target="_blank" >RIV/00023736:_____/24:00013753 - isvavai.cz</a>

  • Result on the web

    <a href="https://doi.org/10.1016/B978-0-443-15717-2.00046-9" target="_blank" >https://doi.org/10.1016/B978-0-443-15717-2.00046-9</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/B978-0-443-15717-2.00046-9" target="_blank" >10.1016/B978-0-443-15717-2.00046-9</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Myelodysplastic syndrome

  • Original language description

    Myelodysplastic neoplasm (MDS) constitute a group of age-associated heterogeneous clonal hematopoietic disorders characterized by the combination of persistent unexplained cytopenias and morphologic dysplasia in one or more of the major hematopoietic cell lines, ineffective hematopoiesis, and an increased risk of progression to acute myeloid leukemia (AML). A conventional karyotype is present in about 50% of cases. Cytogenetic abnormalities based on losses of chromosomal material are most frequent than gains such as trisomy 8 or trisomy 21. Next-generation sequencing found somatic mutations in approximately 90% of patients with MDS. One or more driver mutations are associated with the pathogenesis of MDS in most patients with MDS. The detection of a driver mutation helps in cases when morphology is not diagnostic. Genomics has impact on the classification of MDS. The recently developed fifth edition of the WHO classification of diseases (WHO, 2022) and International Consensus (IC) classification of hematologic neoplasms included MDS with mutated SF3B1 and MDS with mutated TP53 (multi-hit TP53 mutation or TP53 mutation and complex karyotype) entities important for risk stratification. Epigenetic mechanisms, immune dysregulation, and proinflammatory signaling play essential roles in the pathogenesis of MDS. The development of targeted and immune therapies is based on molecular and genetic characterization of MDS, and understanding the pathogenic mechanisms of MDS.

  • Czech name

  • Czech description

Classification

  • Type

    C - Chapter in a specialist book

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2024

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Book/collection name

    Comprehensive hematology and stem cell research: volume 1-5

  • ISBN

    978-044315718-9

  • Number of pages of the result

    26

  • Pages from-to

    "V2:144"-"V2:169"

  • Number of pages of the book

    2572

  • Publisher name

    Elsevier

  • Place of publication

    Amsterdam

  • UT code for WoS chapter